Many US patients opt for obesity drug injections, defying some expectations
By Chris Prentice and Mariam Sunny NEW YORK, July 22 (Reuters) - Many patients have opted for injectable forms of the wildly popular GLP-1 obesity medications through a pilot program of the U.S. government's Medicare health insurance program for Americans aged 65 and older, according to early